Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hannah Chen


Oxford-Celgene Research Fellow

I’m interested in pathogenic tissue remodelling processes during chronic intestinal inflammation and inflammation-driven oncogenesis. I have recently completed a project using single cell RNA sequencing and mass cytometry to interrogate mesenchymal heterogeneity, functional specialisation and changes during inflammation. In my current work, I am investigating the interplay between the T cell, B cell, myeloid and mesenchymal compartments in inflammation. 


  1. Chen HH, Parikh K, Kinchen J, Antanaviciute A, Jagielowicz M, Fawkner-Corbett D, Ashley N, Cubitt L, et al., (2018) Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease. Cell
  2. Chen HH, Händel N, Ngeow J, Muller J, Hühn M, Yang HT, Heindl M, Berbers RM, et al., (2017) Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. Journal of Allergy and Clinical Immunology. PMID: 27477328.
  3. Schwerd T, Khaled AV, Schürmann M, Chen H, Händel N, Reis A, Gillessen-Kaesbach G, Uhlig HH, Abou Jamra R. (2016) A recessive form of extreme macrocephaly and mild intellectual disability complements the spectrum of PTEN hamartoma tumour syndrome. European Journal of Human GeneticsPMID: 26443266.  
  4. Avitzur Y, Guo C, Mastropaolo LA, Bahrami E, Chen H, Zhao Z, Elkadri A, Dhillon S,et al., (2014) Mutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease. Gastroenterology. PMID: 24417819.
  5. Hou W, Chen H, Rojas J, Sampath P, Thorne SH. (2014) Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. International Journal of CancerPMID: 24474587
  6. Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen Het al., (2013) OncolyticVaccinia Virus Disrupts Tumor-Associated Vasculature in Humans. Cancer Research. PMID: 23393196.
  7. Chen H, Sampath P, Hou W, Thorne SH. (2013) Regulating cytokine function enhances safety and activity of genetic cancer therapies. Molecular Therapy. PMID: 23281444.
  8. Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH. (2013) Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Molecular Therapy. PMID: 23229093.
  9. Chen HH, Cawood R, El-Sherbini Y, Purdie L, Bazan-Peregrino M, Seymour LW,Carlisle RC. (2011) Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Molecular Therapy. PMID: 20877345.
  10. Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, Seymour LW. (2009) Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathogen. PMID: 19461878.
  11. Chen HH, Cawood R, Seymour LW. (2008) Toward more effective gene delivery.Genome Biology. PMID: 18226177.

Recent publications

More publications